Join us for an in-depth and thought-provoking episode featuring Alan White, CEO and Co-founder of Arriello, as we explore the evolving world of global regulatory affairs, pharmacovigilance, quality, and compliance—and the powerful intersection of technology and human expertise that is redefining life sciences.

In this conversation, Alan shares his unconventional journey from a commercial career spanning IT, lighting, and translation services into the highly regulated pharmaceutical sector. He reflects on how early exposure to regulatory-driven services inspired him to found Arriello in 2008, during one of the most challenging global financial climates. From building credibility as a new entrant in a trust-based industry to scaling operations across continents, Alan offers a candid look at what it takes to transform a startup into a global organization supporting clients in more than 140 markets.

We dive into Arriello’s evolution from post-marketing regulatory support into a comprehensive strategic advisory partner spanning clinical development, drug safety, and compliance services. Alan unpacks the realities of navigating fragmented global regulatory systems, the importance of local expertise in global market entry, and the common mistakes biotech companies make when expanding internationally. The discussion also explores the growing role of AI and automation in compliance workflows—and why a human-in-the-loop approach remains essential to ensure accuracy, accountability, and sound judgment.

Episode Highlights:
A deep dive into the inspiration and early challenges behind founding Arriello
Insights into building credibility and trust in global regulatory consulting
The transformation from post-marketing support to full-spectrum strategic advisory services
Practical perspectives on integrating AI and automation while preserving human oversight
A forward-looking vision where regulatory affairs and pharmacovigilance become innovation drivers through digital transformation

Whether you're a biotech founder, regulatory professional, or life sciences executive, this episode offers strategic clarity on how compliance, technology, and leadership intersect in today’s global pharmaceutical landscape. Discover how combining digital capability with human expertise is shaping the future of regulatory excellence and accelerating innovation across life sciences.

Join us for an inspiring episode of Lab Bench to Boardroom: Leading Science-Driven Innovation featuring Ashley Zehnder, CEO of Fauna Bio, as we explore the intersection of bold scientific thinking, biotech leadership, and nature-inspired therapeutics. In this conversation, Ashley shares how Fauna Bio is redefining drug discovery by leveraging multi-omics insights from hibernating species to tackle some of the most complex human diseases.

Ashley reflects on her journey from veterinary science to leading a cutting-edge biotech company, offering candid insights into the challenges and opportunities of women in science and executive leadership. She recounts the founding story of Fauna Bio—sparked by a powerful realization that nature has already solved many biological challenges humans face—and how that “aha” moment evolved into a platform built on evolutionary biology and translational science.

We dive into how Fauna Bio integrates genomics, transcriptomics, and proteomics to uncover protective mechanisms embedded in hibernation biology, and how those insights are translated into potential therapeutics. Ashley also discusses the scientific and operational complexities of working with non-traditional model species, building a science-first culture, and scaling innovation while staying grounded in rigorous data.

Episode Highlights:
A deep exploration of women’s leadership and representation in biotech
Ashley Zehnder’s path from veterinary medicine to biotech CEO
The origin story and vision behind Fauna Bio
How hibernation biology can unlock transformative treatments in human health
Real-world examples of translating animal biology into therapeutic pipelines
Leadership lessons from building and scaling a mission-driven biotech company

Whether you're a scientist, entrepreneur, investor, or innovation leader, this episode offers a compelling look at how evolutionary biology and multi-omics technologies are converging to reshape drug discovery. Discover how science drawn from nature—combined with visionary leadership—can drive the next generation of breakthrough therapeutics.

Join us for a powerful and timely episode featuring Golda Naana Boakye, CEO of Naantu, as we examine the urgent need to advance diversity, equity, and inclusion in clinical research. In this compelling conversation, Golda shares why representative clinical trials are not only a matter of social responsibility, but a scientific and clinical imperative essential to improving outcomes for all patients.

We explore the systemic and structural barriers that continue to limit participation from underrepresented communities, from historical mistrust and access challenges to trial design limitations that fail to reflect real-world populations. Golda discusses the importance of rebuilding trust through transparency, meaningful community engagement, and culturally competent communication—shifting clinical research from a transactional model to a patient-centered partnership.

The conversation also highlights how innovative, technology-enabled approaches are helping to remove logistical barriers, expand access, and enhance the participant experience. From decentralized trial models to data-driven outreach strategies, we examine how sponsors and CROs can move beyond intention and toward measurable action in equity-driven research.

Episode Highlights:
A deep dive into why diversity in clinical trials strengthens scientific validity and patient outcomes
Key structural barriers preventing broader participation—and how to address them
The critical role of trust, transparency, and community engagement in recruitment
How digital tools and decentralized models can improve accessibility and inclusivity
Golda’s leadership journey and the mission driving Naantu
Practical strategies for sponsors and research organizations to build more representative trials
A forward-looking vision for patient-centric, equitable clinical research

Whether you're a biopharma executive, clinical researcher, sponsor, or healthcare innovator, this episode offers strategic clarity and actionable insights on building trials that truly reflect the populations they aim to serve. Discover how inclusive research design is shaping the future of medicine—and why equity must be embedded at the core of scientific progress.